Chemo-free treatment approach demonstrates positive responses in leukaemia patients

Compound improves survival in aggressive acute myeloid leukaemia with manageable added toxicity in phase III trial

Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma

Nivolumab shows early promise in Hodgkin lymphoma

Blinatumomab demonstrates significant clinical activity in residual ALL

New immunotherapy compound effective, safe in ALL patients with minimal residual disease

T cell therapy leading to prolonged remission for children with aggressive leukaemia

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

ASH 2014: Expert discussion on the latest in AML

ASH 2014: Expert discussion on the latest in CLL

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma

Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study